Meta Platforms has clawed back $26 in two sessions, closing Tuesday at $570.05 — a 4.9% weekly gain that takes the edge off the worst of the trial-driven selloff, but leaves the stock still 32% below the Street's mean price target of $754.
The recovery is real but fragile in context. Just one week ago, META touched $543.67 — its lowest point since the social media addiction trial re-entered the conversation in early August. The bounce from that trough to $570 is encouraging on its face. But the stock remains down 4.2% over the past month and roughly 17% year-to-date. The July 15 high of $681 is more than $110 away. What's changed this week is the price — not the legal overhang, and not the fundamental gap between where the stock trades and where analysts think it belongs.
The short side offers little drama here. Short interest has fallen sharply — dropping 10.3% on the week and now down 18.6% over the past month to just 1.3% of the free float. That's a low reading for a mega-cap, and the direction of travel confirms what previous reports noted: short sellers are not piling in on this weakness. Cost to borrow has ticked up 71% on the week, but from an extremely low base — it stands at just 0.42%, a level that barely registers in borrowing cost terms. The borrow market remains wide open. Options positioning has edged slightly more defensive, with the put/call ratio at 0.47 versus a 20-day average of 0.45, but the z-score of 1.4 is nothing dramatic — this is call-heavy positioning normalising, not a genuine flight to puts. Shorts haven't built, hedgers haven't panicked. The lending market is about as loose as it gets.
The Street remains structurally bullish, but the targets are in retreat. The clearest recent signal: Evercore ISI's Mark Mahaney raised his target from $820 to $860 on Tuesday, one of the few upward moves in a field that has been cutting. The broader post-Q2 wave — Goldman Sachs, UBS, Citi, TD Cowen and others all trimmed targets on July 30 — pulled the consensus mean price target to $754. Even after those cuts, the implied return from current levels exceeds 32%. That's an enormous gap. The PE now sits near 17.6x on a trailing basis, with EV/EBITDA at roughly 9x — multiples that look compellingly cheap if the advertising business holds and the legal outcome is manageable. The factor scores add nuance: forward earnings growth ranks in the 88th percentile of the universe, dividend score leads at the 96th percentile, but near-term EPS momentum is soft — 30-day EPS momentum ranks in just the 20th percentile, suggesting estimate cuts are still feeding through.
Institutional flows are quietly constructive beneath the surface. Capital Research added over 9.4 million shares in the most recently reported period. BlackRock added 4.6 million. State Street added 3.5 million. None of these are momentum plays — they're index and active managers adding into weakness. Insider activity is less reassuring: CFO Susan Li sold roughly $3.5 million of stock on August 18 across multiple tranches, alongside CLO Curtis Mahoney selling around $870,000. The significance scores on these trades are low, and planned-sale programs are common at large-caps, but the net insider picture over 90 days is broadly neutral rather than directionally bullish.
The next formal catalyst is Q3 earnings, currently scheduled for October 28. Last quarter's print produced a 9.2% single-session decline — the sharpest earnings-day move in the recent data — as the market used the results to reprice both the AI spend trajectory and the legal exposure. The trial outcome between now and late October will likely determine whether the stock closes even a fraction of the 32% gap to the analyst consensus — or whether that gap widens further.
See the live data behind this article on ORTEX.
Open META on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
